NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Yemaachi Biotechnology

Yemaachi Biotechnology

Private
AccraHealthcare & Life Scienceshttps://www.yemaachi.com/

Last Round

Grant

Mar 6, 2024

Est. Valuation

$1.79M

Total Funding Raised

$4.13M

Company Overview

Yemaachi Biotechnology is a precision oncology company that leverages African genomic diversity to develop next-generation cancer diagnostics and therapeutics.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Clinical Trials, Medical AI, Healthcare Analytics

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service, Usage-Based SaaS

AI Layer

Application

Keywords

precision oncologycancer genomicsmolecular diagnosticsbiobankinggenomic databreast cancer screeninggenomic researchbiotechAI-driven diagnosticsbiomarker discoveryclinical researchhuman papillomavirus testHPVctDNA testinghealth techmedtech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Yemaachi Biotechnology Comps

Public and private peers based on sector, stage, and business model.

Yemaachi Biotechnology comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Yemaachi Biotechnology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMar 6, 2024
SeedMar 21, 2022
GrantOct 20, 2021
AcceleratorAug 9, 2021

Key People

Founding team and executive leadership

Yaw Bediako

Chief Executive Officer

Executive Team

Yemaachi Biotechnology Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 18, 2025

    Launching The African Cancer Atlas (TACA) together.

  • Feb 18, 2025

    Launched The African Cancer Atlas in partnership with Roche.

Yemaachi Biotechnology Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Yemaachi Biotechnology Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Yemaachi Biotechnology's valuation, stock price, and market status.

Firmographic Details

HeadquartersAccra
Employee Range49
Year Founded2020
Last FundingMar 6, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.